Literature DB >> 7687760

Hyperplasia, hyperkeratosis and benign tumor production in transgenic mice by a targeted v-fos oncogene suggest a role for fos in epidermal differentiation and neoplasia.

D A Greenhalgh1, J A Rothnagel, X J Wang, M I Quintanilla, C C Orengo, T A Gagne, D S Bundman, M A Longley, C Fisher, D R Roop.   

Abstract

A vector, derived from the human K1 keratin gene, has been employed to target v-fos expression exclusively in the epidermis of transgenic mice. Adult transgenic mice expressors (3-4 months) displayed hyperplasia and hyperkeratosis, initially in wounded (tagged) ears, which later became bilateral. This phenotype appeared at other epidermal sites, most notably in the axilla and inguinal areas. This indicates that a second promoting event, such as wounding or friction, is required to elicit these pathological changes. Highly keratotic benign ear lesions and benign squamous papillomas appeared after long latency at sites of phenotypic epidermis. These data suggest that v-fos may be interfering with c-fos function in normal keratinocyte differentiation, but by itself is insufficient to elicit overt benign lesions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687760

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  The 5' noncoding region of the mouse involucrin gene: comparison with the human gene and genes encoding other cornified envelope precursors.

Authors:  A Gandarillas; F M Watt
Journal:  Mamm Genome       Date:  1995-09       Impact factor: 2.957

2.  Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism.

Authors:  T Hawighorst; P Velasco; M Streit; Y K Hong; T R Kyriakides; L F Brown; P Bornstein; M Detmar
Journal:  EMBO J       Date:  2001-06-01       Impact factor: 11.598

3.  Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition.

Authors:  X J Wang; D A Greenhalgh; J R Bickenbach; A Jiang; D S Bundman; T Krieg; R Derynck; D R Roop
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

Review 4.  Transgenic mice and squamous multistage skin carcinogenesis.

Authors:  K Brown; A Balmain
Journal:  Cancer Metastasis Rev       Date:  1995-06       Impact factor: 9.264

5.  Suprabasal desmoglein 3 expression in the epidermis of transgenic mice results in hyperproliferation and abnormal differentiation.

Authors:  Anita J Merritt; Mohamed Y Berika; Wenwu Zhai; Sarah E Kirk; Baijing Ji; Matthew J Hardman; David R Garrod
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

Review 6.  Murine mentors: transgenic and knockout models of surgical disease.

Authors:  J M Arbeit; R Hirose
Journal:  Ann Surg       Date:  1999-01       Impact factor: 12.969

7.  Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice.

Authors:  J M Arbeit; K Münger; P M Howley; D Hanahan
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Inducible deletion of the Blimp-1 gene in adult epidermis causes granulocyte-dominated chronic skin inflammation in mice.

Authors:  Ming-Feng Chiang; Shii-Yi Yang; I-Ying Lin; Jin-Bon Hong; Sung-Jan Lin; Hsia-Yuan Ying; Chun-Ming Chen; Shih-Ying Wu; Fu-Tong Liu; Kuo-I Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

9.  Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis.

Authors:  J D'Armiento; T DiColandrea; S S Dalal; Y Okada; M T Huang; A H Conney; K Chada
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

10.  Epidermal terminal differentiation depends on B lymphocyte-induced maturation protein-1.

Authors:  Erna Magnúsdóttir; Sergey Kalachikov; Koji Mizukoshi; David Savitsky; Akemi Ishida-Yamamoto; Andrey A Panteleyev; Kathryn Calame
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.